{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:47Z","timestamp":1793400707191,"version":"4.5.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"38","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Institute of Health","award":["R01HL141466"],"award-info":[{"award-number":["R01HL141466"]}]},{"name":"National Institute of Health","award":["R01HL155990"],"award-info":[{"award-number":["R01HL155990"]}]},{"name":"National Institute of Health","award":["R01HL156021"],"award-info":[{"award-number":["R01HL156021"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>With the explosion of anticancer drugs, an emerging concern is the risk for drug-induced sudden death (SD) via ventricular arrhythmias (VA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We used the international pharmacovigilance database VigiBase (n\u2009=\u200918 441 659 reports) to compare drug-induced long QT (diLQT, n\u2009=\u200918 123) and VA (n\u2009=\u200929 193) including torsade de pointes (TdP, n\u2009=\u20098163) reporting for 663 anticancer drugs vs. all other drugs until 01\/01\/2019. The analysis used the 95% lower-end credibility interval of the information component (IC025), an indicator for disproportionate Bayesian reporting; significant when IC025 &amp;gt;0. There were 2301 reports (13.8% fatal) for 40 anticancer drugs significantly associated with diLQT (with 27 also associated with VA or SD) and 9 drugs associated with VA without diLQT. Half of these (46.9%, 23\/49) were associated with SD. Most (41%, 20\/49) were kinase inhibitors, 8% (4\/49) were hormonal therapies, 6% (3\/49) were immunotherapies, 24% (12\/49) were cytotoxics, and 20% (10\/49) were miscellaneous. In VigiBase, reports of diLQT, TdP, or VA increased from 580 in the period 1967\u201383 to 15 070 in 2014\u201318 with the proportion related to anticancer drugs increasing from 0.9% (5\/580) to 14.0% (2115\/15 070) (P\u2009&amp;lt;\u20090.0001). Concordance between these VigiBase signals and data concerning diLQT and VA\/TdP identified in CredibleMeds or US Food and Drug Administration (FDA) labels was moderate (\u03ba\u2009=\u20090.47 and 0.40, P\u2009&amp;lt;\u20090.0001). Twenty-three drugs represent new signals, while 24 flagged by CredibleMeds or FDA had no signal in VigiBase. A three-level SD risk stratification relying on isolated long QT (low risk), associated with VA without SD (moderate risk), and VA with SD (high risk) is proposed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This list of liable anticancer drugs may prove useful for physicians and regulatory authorities to re-evaluate cardiac monitoring requirements.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial registration<\/jats:title>\n                  <jats:p>NCT03530215.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab362","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T19:22:08Z","timestamp":1622056928000},"page":"3915-3928","source":"Crossref","is-referenced-by-count":78,"title":["Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-3307","authenticated-orcid":false,"given":"Joe-Elie","family":"Salem","sequence":"first","affiliation":[{"name":"INSERM, CIC-1901, Sorbonne Universit\u00e9, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Pharmacology, CLIP\u00b2 Galil\u00e9e, Regional Pharmacovigilance Center, UNICO-GRECO Cardio-Oncology Program , Paris 75013, France"},{"name":"Cardio-Oncology Program, Department of Medicine and Pharmacology, Vanderbilt University Medical Center , Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-6269","authenticated-orcid":false,"given":"Lee S","family":"Nguyen","sequence":"additional","affiliation":[{"name":"INSERM, CIC-1901, Sorbonne Universit\u00e9, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Pharmacology, CLIP\u00b2 Galil\u00e9e, Regional Pharmacovigilance Center, UNICO-GRECO Cardio-Oncology Program , Paris 75013, France"},{"name":"Research & Innovation of CMC Ambroise Par\u00e9 , Neuilly-sur-Seine 92200, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J","family":"Moslehi","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Department of Medicine and Pharmacology, Vanderbilt University Medical Center , Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ederhy","sequence":"additional","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Department of Cardiology, AP-HP, Saint Antoine Hospital, UNICO-GRECO Cardio-oncology program , Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-5063","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[{"name":"INSERM, CIC-1901, Sorbonne Universit\u00e9, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Pharmacology, CLIP\u00b2 Galil\u00e9e, Regional Pharmacovigilance Center, UNICO-GRECO Cardio-Oncology Program , Paris 75013, France"},{"name":"UPEC EA EpiDermE , 7379, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6302-0389","authenticated-orcid":false,"given":"Dan M","family":"Roden","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Department of Medicine and Pharmacology, Vanderbilt University Medical Center , Nashville, TN, USA"},{"name":"Department of Biomedical Informatics, Vanderbilt University Medical Center , Nashville, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-5189","authenticated-orcid":false,"given":"Christian","family":"Funck-Brentano","sequence":"additional","affiliation":[{"name":"INSERM, CIC-1901, Sorbonne Universit\u00e9, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Pharmacology, CLIP\u00b2 Galil\u00e9e, Regional Pharmacovigilance Center, UNICO-GRECO Cardio-Oncology Program , Paris 75013, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gougis","sequence":"additional","affiliation":[{"name":"INSERM, CIC-1901, Sorbonne Universit\u00e9, AP-HP, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Department of Pharmacology, CLIP\u00b2 Galil\u00e9e, Regional Pharmacovigilance Center, UNICO-GRECO Cardio-Oncology Program , Paris 75013, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"2022102513561940400_ehab362-B1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","article-title":"Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study","volume":"20","author":"Arnold","year":"2019","journal-title":"Lancet Oncol"},{"key":"2022102513561940400_ehab362-B2","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102513561940400_ehab362-B3","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?","volume":"18","author":"Levis","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022102513561940400_ehab362-B4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","article-title":"Clinical pharmacology and interplay of immune checkpoint agents: a Yin-Yang balance","volume":"61","author":"Geraud","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2022102513561940400_ehab362-B5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2022102513561940400_ehab362-B6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2022102513561940400_ehab362-B7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.119.040162","article-title":"Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes","volume":"140","author":"Salem","year":"2019","journal-title":"Circulation"},{"key":"2022102513561940400_ehab362-B8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/cvr\/cvz013","article-title":"A current understanding of drug-induced QT prolongation and its implications for anticancer therapy","volume":"115","author":"Roden","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2022102513561940400_ehab362-B9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cpt.896","article-title":"Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the \"CiPA\" initiative and design of a prospective clinical validation study","volume":"103","author":"Vicente","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2022102513561940400_ehab362-B10","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102513561940400_ehab362-B11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR Database System: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"2022102513561940400_ehab362-B12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"2022102513561940400_ehab362-B13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2022102513561940400_ehab362-B14","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1136\/heartjnl-2017-312934","article-title":"Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors","volume":"104","author":"Grouthier","year":"2018","journal-title":"Heart"},{"key":"2022102513561940400_ehab362-B15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jamacardio.2018.2251","article-title":"Association of oral contraceptives with drug-induced QT interval prolongation in healthy nonmenopausal women","volume":"3","author":"Salem","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2022102513561940400_ehab362-B16","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"2022102513561940400_ehab362-B17","doi-asserted-by":"crossref","first-page":"e005443","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2022102513561940400_ehab362-B18","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","article-title":"Effect of arsenic trioxide on QT interval in patients with advanced malignancies","volume":"21","author":"Barbey","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022102513561940400_ehab362-B19","doi-asserted-by":"crossref","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022102513561940400_ehab362-B20","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"2022102513561940400_ehab362-B21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00228-015-1831-1","article-title":"Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib","volume":"71","author":"Liu","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"2022102513561940400_ehab362-B22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5603\/CJ.2012.0078","article-title":"QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature","volume":"19","author":"Lynch","year":"2012","journal-title":"Cardiol J"},{"key":"2022102513561940400_ehab362-B23","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102513561940400_ehab362-B24","first-page":"100235","article-title":"Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study","volume":"25","author":"Schaffer","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022102513561940400_ehab362-B25","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"2022102513561940400_ehab362-B26","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102513561940400_ehab362-B27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-017-3253-5","article-title":"Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies","volume":"79","author":"Morcos","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022102513561940400_ehab362-B28","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102513561940400_ehab362-B29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care","volume":"40","author":"Manouchehri","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102513561940400_ehab362-B30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc.2015.18","article-title":"The kinome \u2018at large\u2019 in cancer","volume":"16","author":"Fleuren","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2022102513561940400_ehab362-B31","author":"Woosley"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/38\/3915\/46625179\/ehab362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/38\/3915\/46625179\/ehab362.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:09:48Z","timestamp":1666717788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/38\/3915\/6346756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":31,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2021,8,9]]},"published-print":{"date-parts":[[2021,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab362","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,7]]},"published":{"date-parts":[[2021,8,9]]}}}